Press Releases

Date Title
11/30/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/8/18 Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
11/7/18 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
11/2/18 Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
10/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/24/18 Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
10/18/18 Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018
10/15/18 Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
10/8/18 Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies
10/5/18 Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder
Displaying 81 - 90 of 635